ecancermedicalscience

Research

Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India

3 Nov 2022
Vijay Patil, George Abraham, Madala Ravikrishna, Atanu Bhattacharjee, Vanita Noronha, Deevyashali Parekh, Nandini Menon, Jyoti Bajpai, Kumar Prabhash

Background: Access to cancer care is an issue in low and low middle-income countries. The problem is worse with respect to access to new therapies like checkpoint inhibitors. Hence, we decided to audit our practice in the head and neck and thoracic medical oncology unit from 2015 to 2019 to study the accessibility of checkpoint inhibitors and factors influencing it.

Methods: All patients who were registered in the head and neck and thoracic medical oncology unit between 2015 and 2019 were included in the study. Patients who received immunotherapy were identified from the prospective database of immunotherapy maintained by the department. We made a list of patients who were eligible for immunotherapy per year and identified how many of them received recommended immunotherapy. The indication for eligibility of immunotherapy was based on published pivotal data and it was applicable from the date of publication of the study online. Descriptive statistics were performed. For nominal and ordinal variable percentage with 95% confidence intervals (95% CI) was provided. Factors impacting the accessibility of immunotherapy were identified.

Findings: A total of 15,674 patients were identified who required immunotherapy; out of them only 444 (2.83%, 95% CI: 2.58–3.1) received it. Among head and neck cancer patients, 4.5% (156 out of 3,435) received immunotherapy versus 2.35% (288 out of 12,239) among thoracic cancer patients (p < 0.001). Among the general category (low socioeconomic), 0.29% (28 out of 9,405 ) versus 6.6% (416 out of 6,269) among the private category (high socioeconomic) received immunotherapy (p < 0.001). While 3.7% (361 out of 9,737) among males versus 1.39% (83 out of 5,937) females received immunotherapy (p < 0.001). There was also a temporal trend seen in the accessibility of immunotherapy (p < 0.001).

Conclusion: The accessibility of immunotherapy is below 3% in India. Patients with head and neck cancers, those registered as private category and male patients had higher access to this therapy. There was also a temporal trend observed suggesting increased accessibility over the years.

Related Articles

Ashutosh Mishra, Amit Kumar, Ajay Gogia, Chinmay Bagla, Gajendra Pandit, Jyoti Sharma, Jyoutishman Saikia, Rohan Kapoor, D N Sharma, Atul Batra, Surendra Saini, Supriya Mallick, Nishkarsh Gupta, Brajesh Ratre, Ruchi Rathore, Sandeep Mathur, Sunil Kumar, Suryanarayana Deo
Patricia N Apenteng, Larry Akoko, Vihar Kotecha, Theresia Mwakyembe, Masumbuko Mwashambwa, Rukia Himid, Deo Hando, Charles Komba, Ally Mwanga, Peter Mbele, Paul Itule, Joshua Jackson, Mungeni Misidai, Cameron Gaskill, Doruk Ozgediz, Nathan Brand
Imad Barjij, Sarah Naciri, Sihame Lkhoyaali, Saoussane Kharmoum, Hanane Inrhaouen, Ibrahim Elghissassi, Saber Boutayeb, Hind Mrabti, Hassan Errihani
Mariam Hina, Bilal Mazhar Qureshi, Habiba Zaheer, Bilal Ahmed, Maham Khan, Laraib Khan, Tooba Ali, Fabiha Shakeel, Jawad Ahmad, Muhammad Abdul Wasay Zuberi, Maria Tariq, Nasir Ali, Asim Hafiz, Ahmed Nadeem Abbasi
Moushumi Suryavanshi, Prashant Mehta, Manoj Kumar, Saphalta Bhagmar, Vidit Kapoor, Dushyant Kumar, Sweta Mishra, Bhawna Chauhan